HCK Promotes High-Grade Serous Ovarian Cancer Tumorigenesis through CD44 and NOTCH3 Signaling
High-grade serous ovarian cancer (HGSOC) is a highly aggressive and lethal subtype of ovarian cancer. While most patients initially respond to standard-of-care treatment, the majority will eventually relapse and succumb to their disease. Despite significant advances in our understanding of this dise...
Saved in:
| Published in | Molecular cancer research Vol. 21; no. 10; pp. 1037 - 1049 |
|---|---|
| Main Authors | , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
United States
02.10.2023
|
| Online Access | Get full text |
| ISSN | 1541-7786 1557-3125 1557-3125 |
| DOI | 10.1158/1541-7786.MCR-22-0496 |
Cover
| Abstract | High-grade serous ovarian cancer (HGSOC) is a highly aggressive and lethal subtype of ovarian cancer. While most patients initially respond to standard-of-care treatment, the majority will eventually relapse and succumb to their disease. Despite significant advances in our understanding of this disease, the mechanisms that govern the distinctions between HGSOC with good and poor prognosis remain unclear. In this study, we implemented a proteogenomic approach to analyze gene expression, proteomic and phosphoproteomic profiles of HGSOC tumor samples to identify molecular pathways that distinguish HGSOC tumors relative to clinical outcome. Our analyses identify significant upregulation of hematopoietic cell kinase (HCK) expression and signaling in poor prognostic HGSOC patient samples. Analyses of independent gene expression datasets and immunohistochemistry of patient samples confirmed increased HCK signaling in tumors relative to normal fallopian or ovarian samples and demonstrated aberrant expression in tumor epithelial cells. Consistent with the association between HCK expression and tumor aggressiveness in patient samples, in vitro phenotypic studies showed that HCK can, in part, promote cell proliferation, colony formation, and invasive capacity of cell lines. Mechanistically, HCK mediates these phenotypes, partly through CD44 and NOTCH3-dependent signaling, and inhibiting CD44 or NOTCH3 activity, either genetically or through gamma-secretase inhibitors, can revert HCK-driven phenotypes. Implications: Collectively, these studies establish that HCK acts as an oncogenic driver of HGSOC through aberrant activation of CD44 and NOTCH3 signaling and identifies this network as a potential therapeutic opportunity in a subset of aggressive and recurrent HGSOC patients. |
|---|---|
| AbstractList | High-grade serous ovarian cancer (HGSOC) is a highly aggressive and lethal subtype of ovarian cancer. While most patients initially respond to standard-of-care treatment, the majority will eventually relapse and succumb to their disease. Despite significant advances in our understanding of this disease, the mechanisms that govern the distinctions between HGSOC with good and poor prognosis remain unclear. In this study, we implemented a proteogenomic approach to analyze gene expression, proteomic and phosphoproteomic profiles of HGSOC tumor samples to identify molecular pathways that distinguish HGSOC tumors relative to clinical outcome. Our analyses identify significant upregulation of hematopoietic cell kinase (HCK) expression and signaling in poor prognostic HGSOC patient samples. Analyses of independent gene expression datasets and IHC of patient samples confirmed increased HCK signaling in tumors relative to normal fallopian or ovarian samples and demonstrated aberrant expression in tumor epithelial cells. Consistent with the association between HCK expression and tumor aggressiveness in patient samples, in vitro phenotypic studies showed that HCK can, in part, promote cell proliferation, colony formation, and invasive capacity of cell lines. Mechanistically, HCK mediates these phenotypes, partly through CD44 and NOTCH3-dependent signaling, and inhibiting CD44 or NOTCH3 activity, either genetically or through gamma-secretase inhibitors, can revert HCK-driven phenotypes.High-grade serous ovarian cancer (HGSOC) is a highly aggressive and lethal subtype of ovarian cancer. While most patients initially respond to standard-of-care treatment, the majority will eventually relapse and succumb to their disease. Despite significant advances in our understanding of this disease, the mechanisms that govern the distinctions between HGSOC with good and poor prognosis remain unclear. In this study, we implemented a proteogenomic approach to analyze gene expression, proteomic and phosphoproteomic profiles of HGSOC tumor samples to identify molecular pathways that distinguish HGSOC tumors relative to clinical outcome. Our analyses identify significant upregulation of hematopoietic cell kinase (HCK) expression and signaling in poor prognostic HGSOC patient samples. Analyses of independent gene expression datasets and IHC of patient samples confirmed increased HCK signaling in tumors relative to normal fallopian or ovarian samples and demonstrated aberrant expression in tumor epithelial cells. Consistent with the association between HCK expression and tumor aggressiveness in patient samples, in vitro phenotypic studies showed that HCK can, in part, promote cell proliferation, colony formation, and invasive capacity of cell lines. Mechanistically, HCK mediates these phenotypes, partly through CD44 and NOTCH3-dependent signaling, and inhibiting CD44 or NOTCH3 activity, either genetically or through gamma-secretase inhibitors, can revert HCK-driven phenotypes.Collectively, these studies establish that HCK acts as an oncogenic driver of HGSOC through aberrant activation of CD44 and NOTCH3 signaling and identifies this network as a potential therapeutic opportunity in a subset of patients with aggressive and recurrent HGSOC.IMPLICATIONSCollectively, these studies establish that HCK acts as an oncogenic driver of HGSOC through aberrant activation of CD44 and NOTCH3 signaling and identifies this network as a potential therapeutic opportunity in a subset of patients with aggressive and recurrent HGSOC. High-grade serous ovarian cancer (HGSOC) is a highly aggressive and lethal subtype of ovarian cancer. While most patients initially respond to standard-of-care treatment, the majority will eventually relapse and succumb to their disease. Despite significant advances in our understanding of this disease, the mechanisms that govern the distinctions between HGSOC with good and poor prognosis remain unclear. In this study, we implemented a proteogenomic approach to analyze gene expression, proteomic and phosphoproteomic profiles of HGSOC tumor samples to identify molecular pathways that distinguish HGSOC tumors relative to clinical outcome. Our analyses identify significant upregulation of hematopoietic cell kinase (HCK) expression and signaling in poor prognostic HGSOC patient samples. Analyses of independent gene expression datasets and immunohistochemistry of patient samples confirmed increased HCK signaling in tumors relative to normal fallopian or ovarian samples and demonstrated aberrant expression in tumor epithelial cells. Consistent with the association between HCK expression and tumor aggressiveness in patient samples, in vitro phenotypic studies showed that HCK can, in part, promote cell proliferation, colony formation, and invasive capacity of cell lines. Mechanistically, HCK mediates these phenotypes, partly through CD44 and NOTCH3-dependent signaling, and inhibiting CD44 or NOTCH3 activity, either genetically or through gamma-secretase inhibitors, can revert HCK-driven phenotypes. Implications: Collectively, these studies establish that HCK acts as an oncogenic driver of HGSOC through aberrant activation of CD44 and NOTCH3 signaling and identifies this network as a potential therapeutic opportunity in a subset of aggressive and recurrent HGSOC patients. |
| Author | Gatza, Michael L. Franciosa, Lucyann Rajkarnikar, Resha Rodirguez-Rodriguez, Lorna Khella, Christen A. Mythreye, Karthikeyan |
| Author_xml | – sequence: 1 givenname: Christen A. orcidid: 0000-0002-7464-8702 surname: Khella fullname: Khella, Christen A. – sequence: 2 givenname: Lucyann orcidid: 0009-0007-0989-6201 surname: Franciosa fullname: Franciosa, Lucyann – sequence: 3 givenname: Lorna orcidid: 0000-0002-5909-1774 surname: Rodirguez-Rodriguez fullname: Rodirguez-Rodriguez, Lorna – sequence: 4 givenname: Resha orcidid: 0000-0002-8724-0052 surname: Rajkarnikar fullname: Rajkarnikar, Resha – sequence: 5 givenname: Karthikeyan orcidid: 0000-0001-5478-0098 surname: Mythreye fullname: Mythreye, Karthikeyan – sequence: 6 givenname: Michael L. orcidid: 0000-0001-6796-7791 surname: Gatza fullname: Gatza, Michael L. |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/37342066$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kTlPxDAQhS0E4lj4CSCXNAEfsZ0VFQrHIo5FLJTIcuJJ1ihxwM4i8e9JxNJQUM0U33ujeW8PbfrOA0KHlJxQKrJTKlKaKJXJk_v8KWEsIelUbqBdKoRKOGVic9zXzA7ai_GNEEaokttohyueMiLlLnqd5bf4MXRt10PEM1cvk-tgLOAFhG4V8fzTBGc8zo0vIeDnVdsFV4OH6CLulwNTL3F-kabYeIsf5s_5jOOFq71pnK_30VZlmggH6zlBL1eXA5Lcza9v8vO7pORk2idAOBGElLKEktJCGCNlBpyCnTJZkIJTSwk3U1pUUolMFRVRGSksyxSzlbV8go5_fN9D97GC2OvWxRKaxngYvtAsYxmXjKbpgB6t0VXRgtXvwbUmfOnfSAbg7AcoQxdjgEqXrje963wfjGs0JXosQI_h6jFcPRSgGdNjAYNa_FH_Hvhf9w2PfoeE |
| CitedBy_id | crossref_primary_10_1016_j_htct_2023_11_007 crossref_primary_10_1016_j_biopha_2024_116932 |
| Cites_doi | 10.1038/nrdp.2016.61 10.1056/NEJMoa1910962 10.18632/oncotarget.4199 10.18632/oncotarget.3220 10.21873/anticanres.11110 10.1038/nmeth.2651 10.1038/nature11003 10.1056/NEJMoa1810858 10.1084/jem.20160801 10.1182/blood-2009-04-218735 10.3390/cancers9060068 10.1056/NEJMoa1909707 10.1038/icb.2014.39 10.1074/jbc.M109.090043 10.1038/srep02650 10.1097/AOG.0000000000000981 10.1038/nrc3144 10.1016/j.celrep.2022.111066 10.1186/s13045-018-0605-5 10.1016/j.bbadis.2016.11.013 10.1073/pnas.091062498 10.1158/2159-8290.CD-15-0714 10.1038/s41392-020-0199-6 10.1056/NEJMoa1911361 10.1038/ng0506-500 10.1126/science.1235122 10.1158/1535-7163.MCT-06-0334 10.1038/ncomms3126 10.1038/ncomms3612 10.1158/2326-6066.CIR-19-0623 10.1126/scisignal.aax8238 10.1016/j.cell.2009.03.045 10.1186/s13073-018-0590-x 10.1038/ng.2764 10.1186/s13073-020-00786-7 10.4049/jimmunol.1101245 10.1074/jbc.M113.509497 10.1158/1078-0432.CCR-09-1126 10.1158/0008-5472.CAN-13-2066 10.3389/fcell.2021.634044 10.1038/nature10166 10.3389/fmolb.2021.694141 10.1038/nature12634 10.1200/JCO.2020.38.15_suppl.e18040 10.3389/fcell.2017.00018 10.1038/nature03445 10.1038/s41598-018-34753-5 10.1016/j.ebiom.2019.11.009 10.3389/fonc.2020.589601 10.1073/pnas.0912708107 10.3389/fonc.2019.00802 10.1155/2013/846387 10.1038/nbt.2203 10.1158/0008-5472.CAN-05-3870 10.1158/1078-0432.CCR-04-2398 10.1016/j.ccell.2017.03.006 10.1093/bioinformatics/bth078 10.1016/j.annonc.2020.08.2102 10.1186/bcr2234 10.1038/ng.2762 10.1038/ncomms7139 10.1074/jbc.M201212200 10.3322/caac.21654 10.1038/nrc4019 10.1038/s41375-020-0934-6 10.1186/s13046-021-02007-4 10.1016/j.xcrm.2020.100004 10.1200/JCO.19.00194 10.1016/j.cell.2016.05.069 10.1111/j.1600-0854.2005.00307.x 10.1038/s41416-021-01662-w 10.1126/scitranslmed.3004387 10.1038/ncomms9971 10.1186/1755-8794-4-3 |
| ContentType | Journal Article |
| Copyright | 2023 American Association for Cancer Research. |
| Copyright_xml | – notice: 2023 American Association for Cancer Research. |
| DBID | AAYXX CITATION NPM 7X8 |
| DOI | 10.1158/1541-7786.MCR-22-0496 |
| DatabaseName | CrossRef PubMed MEDLINE - Academic |
| DatabaseTitle | CrossRef PubMed MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic PubMed |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Biology |
| EISSN | 1557-3125 |
| EndPage | 1049 |
| ExternalDocumentID | 37342066 10_1158_1541_7786_MCR_22_0496 |
| Genre | Journal Article |
| GroupedDBID | --- 123 18M 2FS 2WC 34G 39C 53G 5RE 5VS AAJMC AAYXX ACGFO ACPRK ADBBV AENEX AFHIN AFRAH AFUMD ALMA_UNASSIGNED_HOLDINGS BAWUL BR6 BTFSW CITATION CS3 DIK DU5 E3Z EBS EJD F5P GX1 HH5 IH2 KQ8 L7B OK1 QTD RCR RHI TR2 W8F WOQ YKV NPM RHF 7X8 |
| ID | FETCH-LOGICAL-c309t-e030500c6cec11b5aa668e31ed926b0b31d103a91bf67587bf0780bd2872dfdd3 |
| ISSN | 1541-7786 1557-3125 |
| IngestDate | Thu Sep 04 15:38:13 EDT 2025 Wed Feb 19 02:23:53 EST 2025 Tue Jul 01 04:31:31 EDT 2025 Thu Apr 24 23:04:24 EDT 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 10 |
| Language | English |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c309t-e030500c6cec11b5aa668e31ed926b0b31d103a91bf67587bf0780bd2872dfdd3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| ORCID | 0000-0002-8724-0052 0009-0007-0989-6201 0000-0002-7464-8702 0000-0001-5478-0098 0000-0002-5909-1774 0000-0001-6796-7791 |
| PMID | 37342066 |
| PQID | 2828362144 |
| PQPubID | 23479 |
| PageCount | 13 |
| ParticipantIDs | proquest_miscellaneous_2828362144 pubmed_primary_37342066 crossref_citationtrail_10_1158_1541_7786_MCR_22_0496 crossref_primary_10_1158_1541_7786_MCR_22_0496 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2023-10-02 |
| PublicationDateYYYYMMDD | 2023-10-02 |
| PublicationDate_xml | – month: 10 year: 2023 text: 2023-10-02 day: 02 |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Molecular cancer research |
| PublicationTitleAlternate | Mol Cancer Res |
| PublicationYear | 2023 |
| References | Poh (2023100207265639300_bib65) 2017; 31 Pujade-Lauraine (2023100207265639300_bib17) 2019; 37 Carréno (2023100207265639300_bib26) 2002; 277 Konstantinopoulos (2023100207265639300_bib10) 2015; 5 Zhou (2023100207265639300_bib54) 2019; 9 Xiu (2023100207265639300_bib53) 2021; 8 McDermott (2023100207265639300_bib68) 2020; 1 Fan (2023100207265639300_bib48) 2011; 4 Girda (2023100207265639300_bib72) 2020; 38 Matulonis (2023100207265639300_bib4) 2016; 2 Yang (2023100207265639300_bib6) 2018; 10 González-Martín (2023100207265639300_bib11) 2019; 381 Ciriello (2023100207265639300_bib9) 2013; 45 Shonibare (2023100207265639300_bib36) 2022; 40 Tibes (2023100207265639300_bib37) 2006; 5 Cancer Genome Atlas Research Network (2023100207265639300_bib8) 2011; 474 Cougoule (2023100207265639300_bib21) 2010; 115 Farmer (2023100207265639300_bib15) 2005; 434 Goldman (2023100207265639300_bib30) 2015; 6 Kandoth (2023100207265639300_bib62) 2013; 502 Hilal (2023100207265639300_bib7) 2016; 36 Lo Riso (2023100207265639300_bib5) 2020; 12 Pelletier (2023100207265639300_bib70) 2006; 66 Vogelstein (2023100207265639300_bib60) 2013; 339 Pene-Dumitrescu (2023100207265639300_bib29) 2010; 285 Tamborero (2023100207265639300_bib63) 2013; 3 Domcke (2023100207265639300_bib46) 2013; 4 Kopan (2023100207265639300_bib71) 2009; 137 Li (2023100207265639300_bib28) 2021; 40 Chen (2023100207265639300_bib51) 2018; 11 Juneja (2023100207265639300_bib74) 2017; 214 Rody (2023100207265639300_bib40) 2009; 11 Kurimchak (2023100207265639300_bib67) 2020; 13 Aran (2023100207265639300_bib31) 2015; 6 Reich (2023100207265639300_bib33) 2006; 38 Tusher (2023100207265639300_bib39) 2001; 98 Karagoz (2023100207265639300_bib34) 2019; 50 Weinstein (2023100207265639300_bib59) 2013; 45 Cougoule (2023100207265639300_bib27) 2005; 6 Roversi (2023100207265639300_bib24) 2021; 9 Huang (2023100207265639300_bib42) 2018; 8 Coleman (2023100207265639300_bib12) 2019; 381 Zhang (2023100207265639300_bib18) 2016; 166 Hofree (2023100207265639300_bib61) 2013; 10 Lantermans (2023100207265639300_bib64) 2021; 35 Poh (2023100207265639300_bib66) 2020; 8 Lili (2023100207265639300_bib43) 2013; 2013 Roversi (2023100207265639300_bib69) 2017; 1863 de Hoon (2023100207265639300_bib35) 2004; 20 Poh (2023100207265639300_bib41) 2015; 6 Gatza (2023100207265639300_bib58) 2010; 107 Siegel (2023100207265639300_bib1) 2021; 71 Cress (2023100207265639300_bib55) 2015; 126 Yoshihara (2023100207265639300_bib32) 2013; 4 Dwyer (2023100207265639300_bib25) 2017; 9 Ray-Coquard (2023100207265639300_bib16) 2019; 381 Martincuks (2023100207265639300_bib50) 2020; 10 Vaughan (2023100207265639300_bib3) 2011; 11 Wang (2023100207265639300_bib19) 2020; 5 Fotopoulou (2023100207265639300_bib56) 2022; 126 Senbanjo (2023100207265639300_bib49) 2017; 5 Carter (2023100207265639300_bib38) 2012; 30 Bowtell (2023100207265639300_bib2) 2015; 15 Guiet (2023100207265639300_bib20) 2011; 187 Hu (2023100207265639300_bib52) 2014; 74 Barretina (2023100207265639300_bib45) 2012; 483 Berchuck (2023100207265639300_bib57) 2005; 11 Troegeler (2023100207265639300_bib23) 2014; 92 Moore (2023100207265639300_bib13) 2018; 379 Gao (2023100207265639300_bib73) 2015; 6 Park (2023100207265639300_bib22) 2014; 289 Miller (2023100207265639300_bib14) 2020; 31 Saito (2023100207265639300_bib44) 2013; 5 Troester (2023100207265639300_bib47) 2009; 15 |
| References_xml | – volume: 2 start-page: 16061 year: 2016 ident: 2023100207265639300_bib4 article-title: Ovarian cancer publication-title: Nat Rev Dis Primers doi: 10.1038/nrdp.2016.61 – volume: 381 start-page: 2391 year: 2019 ident: 2023100207265639300_bib11 article-title: Niraparib in patients with newly diagnosed advanced ovarian cancer publication-title: N Engl J Med doi: 10.1056/NEJMoa1910962 – volume: 6 start-page: 15752 year: 2015 ident: 2023100207265639300_bib41 article-title: Hematopoietic cell kinase (HCK) as a therapeutic target in immune and cancer cells publication-title: Oncotarget doi: 10.18632/oncotarget.4199 – volume: 6 start-page: 9313 year: 2015 ident: 2023100207265639300_bib73 article-title: Up-regulation of CD44 in the development of metastasis, recurrence and drug resistance of ovarian cancer publication-title: Oncotarget doi: 10.18632/oncotarget.3220 – volume: 36 start-page: 5365 year: 2016 ident: 2023100207265639300_bib7 article-title: What characterizes long-term survivors of recurrent ovarian cancer? Case report and review of the literature publication-title: Anticancer Res doi: 10.21873/anticanres.11110 – volume: 10 start-page: 1108 year: 2013 ident: 2023100207265639300_bib61 article-title: Network-based stratification of tumor mutations publication-title: Nat Methods doi: 10.1038/nmeth.2651 – volume: 483 start-page: 603 year: 2012 ident: 2023100207265639300_bib45 article-title: The cancer cell line encyclopedia enables predictive modelling of anticancer drug sensitivity publication-title: Nature doi: 10.1038/nature11003 – volume: 379 start-page: 2495 year: 2018 ident: 2023100207265639300_bib13 article-title: Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer publication-title: N Engl J Med doi: 10.1056/NEJMoa1810858 – volume: 214 start-page: 895 year: 2017 ident: 2023100207265639300_bib74 article-title: PD-L1 on tumor cells is sufficient for immune evasion in immunogenic tumors and inhibits CD8 T cell cytotoxicity publication-title: J Exp Med doi: 10.1084/jem.20160801 – volume: 115 start-page: 1444 year: 2010 ident: 2023100207265639300_bib21 article-title: Three-dimensional migration of macrophages requires Hck for podosome organization and extracellular matrix proteolysis publication-title: Blood doi: 10.1182/blood-2009-04-218735 – volume: 9 start-page: 68 year: 2017 ident: 2023100207265639300_bib25 article-title: Promotion of tumor invasion by tumor-associated macrophages: the role of CSF-1-activated phosphatidylinositol 3 kinase and SRC family kinase motility signaling publication-title: Cancers doi: 10.3390/cancers9060068 – volume: 381 start-page: 2403 year: 2019 ident: 2023100207265639300_bib12 article-title: Veliparib with first-line chemotherapy and as maintenance therapy in ovarian cancer publication-title: N Engl J Med doi: 10.1056/NEJMoa1909707 – volume: 92 start-page: 699 year: 2014 ident: 2023100207265639300_bib23 article-title: An efficient siRNA-mediated gene silencing in primary human monocytes, dendritic cells and macrophages publication-title: Immunol Cell Biol doi: 10.1038/icb.2014.39 – volume: 285 start-page: 21446 year: 2010 ident: 2023100207265639300_bib29 article-title: Expression of a SRC family kinase in chronic myelogenous leukemia cells induces resistance to imatinib in a kinase-dependent manner publication-title: J Biol Chem doi: 10.1074/jbc.M109.090043 – volume: 3 start-page: 2650 year: 2013 ident: 2023100207265639300_bib63 article-title: Comprehensive identification of mutational cancer driver genes across 12 tumor types publication-title: Sci Rep doi: 10.1038/srep02650 – volume: 126 start-page: 491 year: 2015 ident: 2023100207265639300_bib55 article-title: Characteristics of long-term survivors of epithelial ovarian cancer publication-title: Obstet Gynecol doi: 10.1097/AOG.0000000000000981 – volume: 11 start-page: 719 year: 2011 ident: 2023100207265639300_bib3 article-title: Rethinking ovarian cancer: recommendations for improving outcomes publication-title: Nat Rev Cancer doi: 10.1038/nrc3144 – volume: 40 start-page: 111066 year: 2022 ident: 2023100207265639300_bib36 article-title: Reciprocal SOX2 regulation by SMAD1-SMAD3 is critical for anoikis resistance and metastasis in cancer publication-title: Cell Rep doi: 10.1016/j.celrep.2022.111066 – volume: 11 start-page: 64 year: 2018 ident: 2023100207265639300_bib51 article-title: The biology and role of CD44 in cancer progression: therapeutic implications publication-title: J Hematol Oncol doi: 10.1186/s13045-018-0605-5 – volume: 1863 start-page: 450 year: 2017 ident: 2023100207265639300_bib69 article-title: Hematopoietic cell kinase (HCK) is a potential therapeutic target for dysplastic and leukemic cells due to integration of erythropoietin/PI3K pathway and regulation of erythropoiesis: HCK in erythropoietin/PI3K pathway publication-title: Biochim Biophys Acta Mol Basis Dis doi: 10.1016/j.bbadis.2016.11.013 – volume: 98 start-page: 5116 year: 2001 ident: 2023100207265639300_bib39 article-title: Significance analysis of microarrays applied to the ionizing radiation response publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.091062498 – volume: 5 start-page: 1137 year: 2015 ident: 2023100207265639300_bib10 article-title: Homologous recombination deficiency: exploiting the fundamental vulnerability of ovarian cancer publication-title: Cancer Discov doi: 10.1158/2159-8290.CD-15-0714 – volume: 5 start-page: 137 year: 2020 ident: 2023100207265639300_bib19 article-title: Targeted therapies in gynecological cancers: a comprehensive review of clinical evidence publication-title: Signal Transduct Target Ther doi: 10.1038/s41392-020-0199-6 – volume: 381 start-page: 2416 year: 2019 ident: 2023100207265639300_bib16 article-title: Olaparib plus bevacizumab as first-line maintenance in ovarian cancer publication-title: N Engl J Med doi: 10.1056/NEJMoa1911361 – volume: 38 start-page: 500 year: 2006 ident: 2023100207265639300_bib33 article-title: GenePattern 2.0 publication-title: Nat Genet doi: 10.1038/ng0506-500 – volume: 339 start-page: 1546 year: 2013 ident: 2023100207265639300_bib60 article-title: Cancer genome landscapes publication-title: Science doi: 10.1126/science.1235122 – volume: 5 start-page: 2512 year: 2006 ident: 2023100207265639300_bib37 article-title: Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells publication-title: Mol Cancer Ther doi: 10.1158/1535-7163.MCT-06-0334 – volume: 4 start-page: 2126 year: 2013 ident: 2023100207265639300_bib46 article-title: Evaluating cell lines as tumour models by comparison of genomic profiles publication-title: Nat Commun doi: 10.1038/ncomms3126 – volume: 4 start-page: 2612 year: 2013 ident: 2023100207265639300_bib32 article-title: Inferring tumour purity and stromal and immune cell admixture from expression data publication-title: Nat Commun doi: 10.1038/ncomms3612 – volume: 8 start-page: 428 year: 2020 ident: 2023100207265639300_bib66 article-title: Inhibition of the SRC kinase HCK impairs STAT3-dependent gastric tumor growth in mice publication-title: Cancer Immunol Res doi: 10.1158/2326-6066.CIR-19-0623 – volume: 13 start-page: eaax8238 year: 2020 ident: 2023100207265639300_bib67 article-title: Functional proteomics interrogation of the kinome identifies MRCKA as a therapeutic target in high-grade serous ovarian carcinoma publication-title: Sci Signal doi: 10.1126/scisignal.aax8238 – volume: 137 start-page: 216 year: 2009 ident: 2023100207265639300_bib71 article-title: The canonical notch signaling pathway: unfolding the activation mechanism publication-title: Cell doi: 10.1016/j.cell.2009.03.045 – volume: 10 start-page: 81 year: 2018 ident: 2023100207265639300_bib6 article-title: Landscape of genomic alterations in high-grade serous ovarian cancer from exceptional long- and short-term survivors publication-title: Genome Med doi: 10.1186/s13073-018-0590-x – volume: 45 start-page: 1113 year: 2013 ident: 2023100207265639300_bib59 article-title: The Cancer Genome Atlas pan-cancer analysis project publication-title: Nat Genet doi: 10.1038/ng.2764 – volume: 12 start-page: 94 year: 2020 ident: 2023100207265639300_bib5 article-title: A cell-of-origin epigenetic tracer reveals clinically distinct subtypes of high-grade serous ovarian cancer publication-title: Genome Med doi: 10.1186/s13073-020-00786-7 – volume: 187 start-page: 3806 year: 2011 ident: 2023100207265639300_bib20 article-title: The process of macrophage migration promotes matrix metalloproteinase-independent invasion by tumor cells publication-title: J Immunol doi: 10.4049/jimmunol.1101245 – volume: 289 start-page: 7897 year: 2014 ident: 2023100207265639300_bib22 article-title: Tyrosine phosphorylation of Wiskott-Aldrich syndrome protein (WASP) by Hck regulates macrophage function publication-title: J Biol Chem doi: 10.1074/jbc.M113.509497 – volume: 15 start-page: 7020 year: 2009 ident: 2023100207265639300_bib47 article-title: Activation of host wound responses in breast cancer microenvironment publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-09-1126 – volume: 74 start-page: 3282 year: 2014 ident: 2023100207265639300_bib52 article-title: Notch3 pathway alterations in ovarian cancer publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-13-2066 – volume: 9 start-page: 634044 year: 2021 ident: 2023100207265639300_bib24 article-title: Hematopoietic cell kinase (HCK) is a player of the crosstalk between hematopoietic cells and bone marrow niche through CXCL12/CXCR4 axis publication-title: Front Cell Dev Biol doi: 10.3389/fcell.2021.634044 – volume: 474 start-page: 609 year: 2011 ident: 2023100207265639300_bib8 article-title: Integrated genomic analyses of ovarian carcinoma publication-title: Nature doi: 10.1038/nature10166 – volume: 8 start-page: 694141 year: 2021 ident: 2023100207265639300_bib53 article-title: The role of Notch3 signaling in cancer stemness and chemoresistance: molecular mechanisms and targeting strategies publication-title: Front Mol Biosci doi: 10.3389/fmolb.2021.694141 – volume: 502 start-page: 333 year: 2013 ident: 2023100207265639300_bib62 article-title: Mutational landscape and significance across 12 major cancer types publication-title: Nature doi: 10.1038/nature12634 – volume: 38 start-page: e18040 year: 2020 ident: 2023100207265639300_bib72 article-title: Open label phase I trial using SPL-108 in combination with weekly paclitaxel final report with molecular correlates publication-title: J Clin Oncol doi: 10.1200/JCO.2020.38.15_suppl.e18040 – volume: 5 start-page: 18 year: 2017 ident: 2023100207265639300_bib49 article-title: CD44: a multifunctional cell surface adhesion receptor is a regulator of progression and metastasis of cancer cells publication-title: Front Cell Dev Biol doi: 10.3389/fcell.2017.00018 – volume: 434 start-page: 917 year: 2005 ident: 2023100207265639300_bib15 article-title: Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy publication-title: Nature doi: 10.1038/nature03445 – volume: 8 start-page: 16444 year: 2018 ident: 2023100207265639300_bib42 article-title: Machine learning predicts individual cancer patient responses to therapeutic drugs with high accuracy publication-title: Sci Rep doi: 10.1038/s41598-018-34753-5 – volume: 50 start-page: 191 year: 2019 ident: 2023100207265639300_bib34 article-title: Integrative proteogenomic analyses of human tumours identifies ADNP as a novel oncogenic mediator of cell cycle progression in high-grade serous ovarian cancer with poor prognosis publication-title: EBioMedicine doi: 10.1016/j.ebiom.2019.11.009 – volume: 10 start-page: 589601 year: 2020 ident: 2023100207265639300_bib50 article-title: CD44 in ovarian cancer progression and therapy resistance—a critical role for STAT3 publication-title: Front Oncol doi: 10.3389/fonc.2020.589601 – volume: 107 start-page: 6994 year: 2010 ident: 2023100207265639300_bib58 article-title: A pathway-based classification of human breast cancer publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.0912708107 – volume: 9 start-page: 802 year: 2019 ident: 2023100207265639300_bib54 article-title: CD44 expression predicts prognosis of ovarian cancer patients through promoting epithelial-mesenchymal transition (EMT) by regulating snail, ZEB1, and caveolin-1 publication-title: Front Oncol doi: 10.3389/fonc.2019.00802 – volume: 2013 start-page: 846387 year: 2013 ident: 2023100207265639300_bib43 article-title: Molecular profiling predicts the existence of two functionally distinct classes of ovarian cancer stroma publication-title: Biomed Res Int doi: 10.1155/2013/846387 – volume: 30 start-page: 413 year: 2012 ident: 2023100207265639300_bib38 article-title: Absolute quantification of somatic DNA alterations in human cancer publication-title: Nat Biotechnol doi: 10.1038/nbt.2203 – volume: 66 start-page: 3681 year: 2006 ident: 2023100207265639300_bib70 article-title: Gamma-secretase-dependent proteolysis of CD44 promotes neoplastic transformation of rat fibroblastic cells publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-05-3870 – volume: 11 start-page: 3686 year: 2005 ident: 2023100207265639300_bib57 article-title: Patterns of gene expression that characterize long-term survival in advanced stage serous ovarian cancers publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-04-2398 – volume: 31 start-page: 563 year: 2017 ident: 2023100207265639300_bib65 article-title: Inhibition of hematopoietic cell kinase activity suppresses myeloid cell-mediated colon cancer progression publication-title: Cancer Cell doi: 10.1016/j.ccell.2017.03.006 – volume: 20 start-page: 1453 year: 2004 ident: 2023100207265639300_bib35 article-title: Open source clustering software publication-title: Bioinformatics doi: 10.1093/bioinformatics/bth078 – volume: 31 start-page: 1606 year: 2020 ident: 2023100207265639300_bib14 article-title: ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer publication-title: Ann Oncol doi: 10.1016/j.annonc.2020.08.2102 – volume: 11 start-page: R15 year: 2009 ident: 2023100207265639300_bib40 article-title: T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers publication-title: Breast Cancer Res doi: 10.1186/bcr2234 – volume: 45 start-page: 1127 year: 2013 ident: 2023100207265639300_bib9 article-title: Emerging landscape of oncogenic signatures across human cancers publication-title: Nat Genet doi: 10.1038/ng.2762 – volume: 6 start-page: 6139 year: 2015 ident: 2023100207265639300_bib30 article-title: Temporally sequenced anticancer drugs overcome adaptive resistance by targeting a vulnerable chemotherapy-induced phenotypic transition publication-title: Nat Commun doi: 10.1038/ncomms7139 – volume: 277 start-page: 21007 year: 2002 ident: 2023100207265639300_bib26 article-title: p59Hck isoform induces F-actin reorganization to form protrusions of the plasma membrane in a Cdc42- and Rac-dependent manner publication-title: J Biol Chem doi: 10.1074/jbc.M201212200 – volume: 71 start-page: 7 year: 2021 ident: 2023100207265639300_bib1 article-title: Cancer Statistics, 2021 publication-title: CA Cancer J Clin doi: 10.3322/caac.21654 – volume: 15 start-page: 668 year: 2015 ident: 2023100207265639300_bib2 article-title: Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer publication-title: Nat Rev Cancer doi: 10.1038/nrc4019 – volume: 35 start-page: 881 year: 2021 ident: 2023100207265639300_bib64 article-title: Identification of the SRC-family tyrosine kinase HCK as a therapeutic target in mantle cell lymphoma publication-title: Leukemia doi: 10.1038/s41375-020-0934-6 – volume: 40 start-page: 210 year: 2021 ident: 2023100207265639300_bib28 article-title: HCK maintains the self-renewal of leukaemia stem cells via CDK6 in AML publication-title: J Exp Clin Cancer Res doi: 10.1186/s13046-021-02007-4 – volume: 1 start-page: 100004 year: 2020 ident: 2023100207265639300_bib68 article-title: Proteogenomic characterization of ovarian HGSC implicates mitotic kinases, replication stress in observed chromosomal instability publication-title: Cell Rep Med doi: 10.1016/j.xcrm.2020.100004 – volume: 37 start-page: 2437 year: 2019 ident: 2023100207265639300_bib17 article-title: Management of platinum-resistant, relapsed epithelial ovarian cancer and new drug perspectives publication-title: J Clin Oncol doi: 10.1200/JCO.19.00194 – volume: 166 start-page: 755 year: 2016 ident: 2023100207265639300_bib18 article-title: Integrated proteogenomic characterization of human high-grade serous ovarian cancer publication-title: Cell doi: 10.1016/j.cell.2016.05.069 – volume: 6 start-page: 682 year: 2005 ident: 2023100207265639300_bib27 article-title: Activation of the lysosome-associated p61Hck isoform triggers the biogenesis of podosomes publication-title: Traffic doi: 10.1111/j.1600-0854.2005.00307.x – volume: 126 start-page: 1047 year: 2022 ident: 2023100207265639300_bib56 article-title: Validation analysis of the novel imaging-based prognostic radiomic signature in patients undergoing primary surgery for advanced high-grade serous ovarian cancer (HGSOC) publication-title: Br J Cancer doi: 10.1038/s41416-021-01662-w – volume: 5 start-page: 181ra52 year: 2013 ident: 2023100207265639300_bib44 article-title: A pyrrolo-pyrimidine derivative targets human primary AML stem cells in vivo publication-title: Sci Transl Med doi: 10.1126/scitranslmed.3004387 – volume: 6 start-page: 8971 year: 2015 ident: 2023100207265639300_bib31 article-title: Systematic pan-cancer analysis of tumour purity publication-title: Nat Commun doi: 10.1038/ncomms9971 – volume: 4 start-page: 3 year: 2011 ident: 2023100207265639300_bib48 article-title: Building prognostic models for breast cancer patients using clinical variables and hundreds of gene expression signatures publication-title: BMC Med Genomics doi: 10.1186/1755-8794-4-3 |
| SSID | ssj0020176 |
| Score | 2.4292002 |
| Snippet | High-grade serous ovarian cancer (HGSOC) is a highly aggressive and lethal subtype of ovarian cancer. While most patients initially respond to standard-of-care... |
| SourceID | proquest pubmed crossref |
| SourceType | Aggregation Database Index Database Enrichment Source |
| StartPage | 1037 |
| Title | HCK Promotes High-Grade Serous Ovarian Cancer Tumorigenesis through CD44 and NOTCH3 Signaling |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/37342066 https://www.proquest.com/docview/2828362144 |
| Volume | 21 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3rb9MwELfKEIgvCMarvGQkvk0peTiPfkRho9CulSCV-gVZduxMY5ChPpA28cdzFzuPSUEMvkTpRXaiu1_Pd-c7HyGvc6WxpYvnxIWKHaZ16CQ-k44OciECxpQvqwTZeTRZso-rcDUY_OpWl2zlKL_srSv5H6kCDeSKVbL_INlmUiDAPcgXriBhuF5LxpN0ipn-wG29qTI2nPdroTQqAMxsXfwERxj-vylKdn2Q7b5jGyxUbqebpkFP-o6xagdhvsjSSXDw-fQEbXO7oNW9nuomupgkhnPZM4KaWPIU80lFe1qBLtsgqendcb6pHs92-YUoO-VnsKae7PSlA3fwcTsT0J5h3-R2C-rrGcZvzmwuOG5SdYMVvkl787v6NcSwqKl1HukemlXKpmy6Bp_bUbFY2Niv-0OsZwCTEIAXJ9HoOP3kgKcNLlDPWdvzBT9azmY8O1xlN8hNPwbLC03qD9PGXQddVdWm1Z9n67_gNW96X3LVsvmDu1KZLdk9ctf6G_StAc99MtDlPrllOpBe7JPbxza34gH5AmiiNZpoiyZq0EQtmqhBE72CJmrRRBFNFNBEDZpog6aHZHl0CCTHNt9w8sAdbx2NK4Hr5lGuc8-ToRBRlOjA02rsR9KVgadAEmLsyQJ9zlgWYGy6UoEH7qtCqeAR2SvPS_2E0IjBb-XpUErGxtqVbu6JSIcREItEiiFhNeN4bk-mxwYp33jloYYJR35z5DcHfnPf58jvIRk1w36Yo1n-NuBVLRUOShR3xkSpgYMc4w5gyXmMDcljI65myiAOGPY8eHqN0c_InRb1z8nedr3TL8Bo3cqXFbZ-A-OFkwg |
| linkProvider | Flying Publisher |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=HCK+Promotes+High-Grade+Serous+Ovarian+Cancer+Tumorigenesis+through+CD44+and+NOTCH3+Signaling&rft.jtitle=Molecular+cancer+research&rft.au=Khella%2C+Christen+A&rft.au=Franciosa%2C+Lucyann&rft.au=Rodirguez-Rodriguez%2C+Lorna&rft.au=Rajkarnikar%2C+Resha&rft.date=2023-10-02&rft.issn=1557-3125&rft.eissn=1557-3125&rft.volume=21&rft.issue=10&rft.spage=1037&rft_id=info:doi/10.1158%2F1541-7786.MCR-22-0496&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1541-7786&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1541-7786&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1541-7786&client=summon |